University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Eric J. Small, MD

Eric J. Small, MD

Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF
Deputy Director and Chief Scientific Officer; Program Leader, Prostate Cancer Program, UCSF Helen Diller Family Comprehensive Cancer Center
Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research; Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF

Cancer Center Program Memberships

Prostate Cancer

Education

Stanford University, Stanford, CA, BS, 1980, Biology
Case Western Reserve University of Medicine, Cleveland, Ohio, MD, 1985, Medicine
Beth Israel Hospital, Boston, MA, Internship and Residency, 1988, Internal Medicine
University of California San Francisco, CA, Fellowship, 1991, Hematology/Oncology


Professional Experience

  • 1982-1983
    Pathology Fellowship, Department of Pathology, Case Western Reserve Univ., Cleveland, OH
  • 1985-1988
    Internal Medicine Internship and Residency Training Program, Beth Israel Hospital, Boston, MA
  • 1988-1989
    Clinical Fellow, Cancer Research Institute, UCSF, San Francisco, CA
  • 1989-1991
    Research Fellow, Cancer Research Institute, (Dr. Marc Shuman) UCSF, San Francisco, CA
  • 1991-1997
    Assistant Clinical Professor of Medicine, UCSF, San Francisco, CA
  • 1991-present
    Head, Urologic Medical Oncology, Division of Hematology/Oncology, UCSF, San Francisco, CA
  • 1996-present
    Co-Director, Urologic Oncology Program, UCSF, San Francisco, CA
  • 1997-2001
    Associate Clinical Professor of Medicine and Urology, UCSF, San Francisco, CA
  • 1999-present
    Chair, Genitourinary Committee, Cancer and Leukemia Group B (CALGB)
  • 2001-present
    Professor in Residence of Medicine and Urology, UCSF, San Francisco, CA
  • 2007-2009
    Interim Chief, Division of Hematology and Oncology, UCSF, San Francisco, CA
  • 2007-present
    Director, Investigational Trials Resource, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2009-present
    Chief, Division of Hematology/Oncology, UCSF, San Francisco, CA
  • 2009-present
    Deputy Director and Director of Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center

Honors & Awards

  • 1978
    Biomedical Research Grant, The Jackson Laboratory, Bar Harbour, ME
  • 1980
    NIH Research Support Grant, Case Western Reserve University, Cleveland, OH
  • 1984
    Alpha Omega Alpha Honor Medical Society
  • 1997
    Prostate Cancer Foundation Therapy Consortium
  • 2006-present
    Stanford W. and Norman R. Ascherman Endowed Chair

Selected Publications

  1. Perez PM, Hope TA, Behr SC, van Zante A, Small EJ, Flavell RR. Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases. Clin Nucl Med. 2019 Jan; 44(1):e28-e32.
    View on PubMed
  2. Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2018 Dec 20.
    View on PubMed
  3. Aggarwal R, Huang J, Alumkal J, Feng FY, Zhang L, Stuart JM, Small EJ. Reply to A. Dalla Volta et al. J Clin Oncol. 2018 Dec 17; JCO1801487.
    View on PubMed
  4. Behr SC, Aggarwal R, Van Brocklin HF, Flavell RR, Geo K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer. J Nucl Med. 2018 Nov 21.
    View on PubMed
  5. Borno HT, Small EJ. Apalutamide and its use in the treatment of prostate cancer. Future Oncol. 2018 Nov 14.
    View on PubMed
  6. Koshkin VS, Small EJ. Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Ther Adv Urol. 2018 Dec; 10(12):445-454.
    View on PubMed
  7. Mohler JL, Halabi S, Ryan ST, Al-Daghmin A, Sokoloff MH, Steinberg GD, Sanford BL, Eastham JA, Walther PJ, Morris MJ, Small EJ. Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. Prostate Cancer Prostatic Dis. 2018 Nov 01.
    View on PubMed
  8. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 Oct 18; 175(3):889.
    View on PubMed
  9. Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study. Clin Genitourin Cancer. 2018 Sep 24.
    View on PubMed
  10. Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Oct; 19(10):1404-1416.
    View on PubMed
  11. Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 Sep 06; 3(17).
    View on PubMed
  12. Kaplan CP, Siegel A, Leykin Y, Palmer NR, Borno H, Bielenberg J, Livaudais-Toman J, Ryan C, Small EJ. A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy. Contemp Clin Trials Commun. 2018 Dec; 12:60-67.
    View on PubMed
  13. Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. J Natl Compr Canc Netw. 2018 08; 16(8):933-937.
    View on PubMed
  14. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 Jul 26; 174(3):758-769.e9.
    View on PubMed
  15. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 Aug 20; 36(24):2492-2503.
    View on PubMed
  16. Smith MR, Yu MK, Small EJ. Apalutamide and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 06 28; 378(26):2542.
    View on PubMed
  17. Antonarakis ES, Small EJ, Petrylak DP, Quinn DI, Kibel AS, Chang NN, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clin Cancer Res. 2018 Oct 01; 24(19):4662-4671.
    View on PubMed
  18. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 05; 94:115-125.
    View on PubMed
  19. Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, Small EJ, Fong L. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. Clin Genitourin Cancer. 2018 06; 16(3):184-190.e2.
    View on PubMed
  20. Atkins KM, Chen MH, Wu J, Renshaw AA, Loffredo M, Kantoff PW, Small EJ, D'Amico AV. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. Cancer. 2018 Apr 01; 124(7):1383-1390.
    View on PubMed

Go to UCSF Profiles, powered by CTSI